M. Kulyk & Associates’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$11.8M Buy
98,194
+577
+0.6% +$66.6K 2.2% 12
2025
Q4
$10.3M Buy
97,617
+1,078
+1% +$101K 1.96% 16
2025
Q3
$8.1M Buy
96,539
+6,295
+7% +$518K 1.65% 18
2025
Q2
$7.14M Buy
90,244
+15,583
+21% +$1.24M 1.55% 21
2025
Q1
$6.7M Buy
74,661
+6,216
+9% +$580K 1.53% 22
2024
Q4
$6.81M Buy
68,445
+3,573
+6% +$368K 1.47% 23
2024
Q3
$7.37M Buy
64,872
+2,096
+3% +$249K 1.48% 24
2024
Q2
$7.77M Buy
62,776
+394
+0.6% +$50.8K 1.81% 16
2024
Q1
$8.23M Buy
62,382
+1,534
+3% +$189K 1.91% 15
2023
Q4
$6.63M Buy
60,848
+3,720
+7% +$386K 1.55% 24
2023
Q3
$5.88M Buy
57,128
+9,080
+19% +$979K 1.63% 20
2023
Q2
$5.54M Sell
48,048
-1,646
-3% -$187K 1.55% 24
2023
Q1
$5.29M Buy
49,694
+2,211
+5% +$239K 1.6% 25
2022
Q4
$5.27M Buy
47,483
+925
+2% +$94.6K 1.76% 22
2022
Q3
$4.01M Buy
+46,558
New +$4.16M 1.39% 26
2022
Q2
Sell
-3,100
Closed -$254K 102
2022
Q1
$254K Sell
3,100
-1,390
-31% -$110K 0.07% 92
2021
Q4
$344K Buy
4,490
+1,400
+45% +$112K 0.09% 70
2021
Q3
$232K Buy
3,090
+359
+13% +$27.3K 0.07% 66
2021
Q2
$212K Sell
2,731
-131
-5% -$9.74K 0.08% 62
2021
Q1
$211K Sell
2,862
-103
-3% -$7.6K 0.08% 72
2020
Q4
$231K Buy
+2,965
New +$227K 0.13% 49

Other funds holding MRK

M. Kulyk & Associates's MRK Position: Q1 2026 in Review

M. Kulyk & Associates increased its Merck (MRK) stake by 0.59% in Q1 2026, buying an estimated $66.6K and bringing the position to 98,194 shares worth $11.8M. The position accounts for 2.2% of the portfolio, ranked #12.

M. Kulyk & Associates first reported a position in MRK in Q4 2020 and has held it in 21 quarters since. 3,778 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • M. Kulyk & Associates held 98,194 shares of Merck worth $11.8M as of Q1 2026.
  • M. Kulyk & Associates bought 577 Merck shares in Q1 2026, an estimated $66.6K.
  • Merck made up 2.2% of M. Kulyk & Associates's portfolio in Q1 2026, its #12 holding.
  • M. Kulyk & Associates first reported a position in Merck in Q4 2020 and has held it in 21 quarters since.
  • 3,778 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on M. Kulyk & Associates's 13F filing for Q1 2026, filed 6 May 2026.